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Background
Treatment options approved for pulmonary arterial
hypertension (PAH) failed in secondary forms of pul-
monary hypertension (PH) often related due to decrease
in oxygenation. Therefore we established an animal
model to evaluate different vasodilator mechanisms
under experimental conditions of heterogeneous lung
ventilation in respect to their “desaturation-potential”.
Methods
Single-lung ventilation (right sided) was induced in 7-wk
old minipigs (4-5 kg BW). In each animal 5 repetitive
cycles of 10 min. left lobe blockade were followed by
30 min. bilateral ventilation. Hemodynamics (e.g. mean
pulmonary artery pressure (mPAP), blood pressure (BP))
and arterial hemoglobin saturation (SaO2) were moni-
tored continuously. We compared 5 different groups
(n=6 each): vehicle control group, the endothelin
antagonist bosentan (0.3, 1, 3, 10 mg/kg i.v.), the PDE5
inhibitor sildenafil (3, 10, 30, 100 µg/kg i.v.), and the
sGC stimulators BAY 41-8543 (1, 3, 10, 30 µg/kg i.v.)
and riociguat (1, 3, 10, 30 µg/kg i.v.). The vasodilator
doses were chosen to achieve equal BP reduction.
Cumulative doses of vasoactive compounds were applied
before successive unilateral ventilation and effects on
desaturation (area under the SaO2 curve, AUCSaO2)
and maximal hypoxic mPAP were compared to vehicle
conditions in each animal.
Results
Single-lung ventilation resulted in transient increases in
mPAP and desaturation (=increase in AUCSaO2). The
vasodilators were compared in respect to their ability to
decrease maximal hypoxic mPAP (positive treatment
effect) and AUCSaO2 (unwanted desaturation effect). In
contrast to vehicle treated control animals all vasodila-
tors lead to a dose-dependent decrease in hypoxic
mPAP (Figure 1) and an increase in AUCSaO2 during
successive unilateral ventilation. Maximal changes in
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AUCSaO2 are shown in Figure 2 (mean ± SEM (n=6)).
Conclusion
Beside the equal effects on BP, the studied compounds
reduced hypoxic mPAP to a different extent with the
strongest effect seen with the sGC stimulators (riociguat
and BAY 41-8543) and bosentan. Furthermore, in com-
parison to bosentan and sildenafil the sGC stimulators
were less likely to cause an unwanted decrease in SaO2.
Explorations of these findings in patients with secondary
PH might be warranted.
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